Cephalon, A Target Itself, To Acquire Remainder Of Australian ChemGenex
This article was originally published in PharmAsia News
Executive Summary
Cephalon Inc. announced March 29 that it has struck an agreement with the Australia-based biopharma ChemGenex Pharmaceuticals Ltd. to pay A$159 million ($US $163 million) for the piece of the company it doesn't already own
You may also be interested in...
Australia's QRxPharma Files NDA With U.S. FDA For Combo Opioid That Looks Safer Than Single Compounds
Sydney-headquartered QRxPharma filed in late July its MoxDuo IR (morphine/oxycodone) NDA with U.S. FDA for the treatment of moderate to severe acute pain. The NDA was submitted under the 505(b)(2) pathway, which allows for historical data because the two components of the dual opioid are already approved. Interestingly, the morphine and oxycodone combo appears to be safer than the two single compounds
Australia's QRxPharma Files NDA With U.S. FDA For Combo Opioid That Looks Safer Than Single Compounds
Sydney-headquartered QRxPharma filed in late July its MoxDuo IR (morphine/oxycodone) NDA with U.S. FDA for the treatment of moderate to severe acute pain. The NDA was submitted under the 505(b)(2) pathway, which allows for historical data because the two components of the dual opioid are already approved. Interestingly, the morphine and oxycodone combo appears to be safer than the two single compounds
Valeant Makes Hostile $5.7B Bid for Cephalon
The offer, which Cephalon says its board will respond to during the week of April 4, comes as the company adjusts to life under new CEO J. Kevin Buchi.